title: Clopidogrel versus ticlopidine after intracoronary stent placement.
abstract: OBJECTIVE
  The study compared the safety and efficacy of ticlopidine with clopidogrel in patients receiving coronary stents.
  
  
  BACKGROUND
  Stent thrombosis is reduced when ticlopidine is administered with aspirin. Clopidogrel is similar to ticlopidine in chemical structure and function but has fewer side effects; few data are available about its use in stent patients.
  
  
  METHODS
  We compared 30-day event rates in 500 consecutive coronary stent patients treated with aspirin and clopidogrel (300 mg loading dose immediately prior to stent placement, and 75 mg/day for 14 days) to 827 consecutive stent patients treated with aspirin and ticlopidine (500 mg loading dose and 250 mg twice daily for 14 days).
  
  
  RESULTS
  Patients treated with clopidogrel had more adverse clinical characteristics including older age, more severe angina, and more frequent infarction within the prior 24 h. Nonetheless, mortality was 0.4% in clopidogrel patients versus 1.1% in ticlopidine patients; nonfatal myocardial infarction occurred in 0% versus 0.5%, stent thrombosis in 0.2% versus 0.7%, bypass surgery or repeat angioplasty in 0.4% versus 0.5%, and any event occurred in 0.8% versus 1.6% of patients, respectively (p = NS). Based on the observed 30-day event rate of 1.6% with ticlopidine, the statistical power of the study was 43% to detect an even rate of 0.5% with clopidogrel, and 75% to detect an event rate with of 4% with clopidogrel, with a p value of 0.05.
  
  
  CONCLUSIONS
  These data indicate that clopidogrel can be safely substituted for ticlopidine in patients receiving coronary stents.
authors.affiliation: Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA.
authors.forename: P B
authors.initials: PB
authors.lastname: Berger
authors.forename: M R
authors.initials: MR
authors.lastname: Bell
authors.forename: C S
authors.initials: CS
authors.lastname: Rihal
authors.forename: H
authors.initials: H
authors.lastname: Ting
authors.forename: G
authors.initials: G
authors.lastname: Barsness
authors.forename: K
authors.initials: K
authors.lastname: Garratt
authors.forename: V
authors.initials: V
authors.lastname: Bellot
authors.forename: V
authors.initials: V
authors.lastname: Mathew
authors.forename: S
authors.initials: S
authors.lastname: Melby
authors.forename: L
authors.initials: L
authors.lastname: Hammes
authors.forename: D
authors.initials: D
authors.lastname: Grill
authors.forename: D R
authors.initials: DR
authors.lastname: Holmes
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D017023:Coronary Angiography; D003328:Coronary Thrombosis / Q000000981:diagnostic imaging / Q000401:mortality / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011446:Prospective Studies; D012449:Safety; D055502:Secondary Prevention; D015607:Stents; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin